Highlights Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.88 ^USD	+0.52%		+11.17%	+48.66%

Apr. 11	Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors	CI
Apr. 09	Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	RE

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	Apr. 01	MT
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials	Mar. 22	MT
Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 22	CI
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	Mar. 18	MT
Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic	Mar. 14	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	Mar. 05	MT
Summit Therapeutics Q4 Loss Widens	Feb. 20	MT
Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Summit Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20	CI
North American Morning Briefing : Earnings Back in -2-	Feb. 20	DJ
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference	Jan. 08	CI
Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Summit Therapeutics' Q2 Net Loss Narrows	23-08-09	MT
Summit Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Summit Therapeutics Inc. Announces Data for its Novel, Potential First-In-Class Investigational Bispecific Antibody,ivonescimab	23-06-01	CI
Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab	23-05-09	CI
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab	23-05-03	CI
Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Summit Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Highlights

Filters